Company Overview - ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment and improving patient survival [2] - The company's lead candidate, evorpacept, is positioned as a potential cornerstone therapy in immuno-oncology and is currently undergoing multiple clinical trials across various cancer indications [2] - ALX Oncology's second candidate, ALX2004, is an innovative EGFR-targeted antibody-drug conjugate expected to enter Phase 1 trials in mid-2025 [2] Financial Reporting - ALX Oncology plans to report its first quarter 2025 financial results on May 8, 2025, before the market opens [1] - The company will not hold a teleconference in conjunction with the financial results press release [1]

– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2 ...

NEW YORK, May 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in May: May 3-6: Digestive Disease Week (DDW). Two abstracts discussing Immunic's phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 ...

NEW YORK, May 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/p ...

Financial Data and Key Metrics Changes - Net sales for Q1 2025 were approximately $585 million, representing a 4.2% decline compared to $611 million in Q1 2024. On a currency neutral basis, this reflects a 1.5% year-over-year decrease, primarily driven by lower sales in the Life Science Group [11][12] - GAAP gross margin for Q1 2025 was 52.3%, down from 53.4% in Q1 2024, attributed to increased restructuring costs [13] - Non-GAAP gross margin for Q1 2025 was 53.8%, lower than 54.2% in Q1 2024, while non-GAAP operating margin improved to 10.8% from 9.7% year-over-year [15][16] - GAAP net income for Q1 2025 was $71 million, or $2.54 diluted earnings per share [17] Business Line Data and Key Metrics Changes - Life Science Group sales in Q1 2025 were $229 million, down 5.4% on a reported basis and 3.5% on a currency neutral basis, reflecting ongoing softness in the biotech and academic research market [12] - Clinical Diagnostics Group sales were approximately $357 million, a decrease of 3.2% on a reported basis, but effectively flat on a currency neutral basis [13] - Process Chromatography business experienced mid-teens growth year-over-year, with expectations of high single-digit growth for 2025 [12][19] Market Data and Key Metrics Changes - In the Americas and Asia Pacific, currency neutral sales decreased, partially offset by increased sales in EMEA [12] - Demand for consumables remained strong, while instrument sales faced challenges, particularly in the academic and biotech sectors [41][71] Company Strategy and Development Direction - The company is focused on driving consistent top-line growth and operational efficiency to achieve substantial margin expansion over the coming years [27] - The acquisition of Stila Technology is on track for closing by the end of Q3 2025, which will enhance the company's digital PCR offerings [8][10] - The company is implementing mitigation strategies for tariff impacts, including surcharges and regionalizing supply chains [7][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging macro environment with academic market headwinds due to government funding and global trade disruptions [5] - The company expects total currency neutral revenue to decline by approximately 1% to 1.5% for 2025, reflecting softer academic research funding and reduced demand from biotech customers [20][21] - Management remains optimistic about the long-term growth potential in life sciences and diagnostics despite current challenges [28][29] Other Important Information - The company generated $130 million in net cash from operating activities in Q1 2025, compared to $70 million in Q1 2024 [18] - Free cash flow for Q1 2025 was $96 million, significantly higher than $30 million in Q1 2024, with a full-year target of approximately $310 million to $330 million for 2025 [18][19] Q&A Session Summary Question: Impact of tariffs on guidance - Management discussed the gross impact of tariffs and mitigation efforts, including potential surcharges and pre-positioning inventory [33][36] Question: Academic funding expectations - Management noted a 28% reduction in overall funding and challenges in instrument sales, while consumables remained strong [39][40] Question: Growth gap between consumables and equipment - Instrument sales saw a sequential decline of about 10%, while consumables held up well [46] Question: Tariff exposure specifics - Management clarified that the majority of revenue in China comes from U.S. products, with ongoing evaluations of tariff impacts [47][49] Question: Free cash flow maintenance despite lower operating margin - Management emphasized focus on working capital management and inventory control to sustain free cash flow [96]

NEW YORK, May 1, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Kronos Bio, Inc. (NASDAQ: KRON), relating to the proposed merger with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash ...

Core Insights - Shattuck Labs, Inc. is advancing its SL-325 program with an IND filing expected in the third quarter of 2025, targeting inflammatory bowel disease (IBD) and other immune-mediated diseases [1][5][9] - The company reported a cash balance of approximately $60.9 million as of March 31, 2025, which is expected to fund operations into 2027 [1][8] Company Developments - SL-325 is a potentially first-in-class DR3 antagonist antibody designed to block the DR3/TL1A pathway, with the Phase 1 clinical trial set to evaluate safety, tolerability, and pharmacokinetics [5][9] - The first patient for the SAD portion of the Phase 1 trial is expected to be enrolled in the third quarter of 2025, with completion of enrollment anticipated by the second quarter of 2026 [5][9] - The company has completed wind-down activities related to discontinued oncology programs and is well-positioned to fund operations beyond the Phase 1 trial results [2][5] Financial Performance - For the first quarter of 2025, Shattuck Labs reported R&D expenses of $9.9 million, down from $16.3 million in the same quarter of 2024, and G&A expenses of $4.5 million, slightly down from $4.9 million [12][19] - The net loss for the quarter was $13.7 million, or $0.27 per share, compared to a net loss of $18.5 million, or $0.37 per share, in the first quarter of 2024 [12][19] - Cash and cash equivalents decreased from $114.6 million as of March 31, 2024, to $60.9 million as of March 31, 2025 [12][19] Upcoming Events - Shattuck Labs participated in the 24th Annual Needham Virtual Healthcare Conference and presented at the ECCO in February 2025 [5][12] - The company is scheduled to present at the PEGS Boston Summit on May 12, 2025, and will participate in the Leerink Partners Therapeutics Forum on July 8-9, 2025 [12]

Core Insights - Adaptive Biotechnologies reported a strong start to 2025 with a 34% growth in MRD revenue, driven by increased clonoSEQ test volume and effective execution [2][4] - The company raised its full-year MRD revenue guidance to a range of $180 million to $190 million, while reducing operating expenses and cash burn targets [2][7][8] Recent Highlights - Revenue for Q1 2025 was $52.4 million, a 25% increase from Q1 2024 [4] - MRD revenue was $43.7 million, reflecting a 34% increase year-over-year, while Immune Medicine revenue decreased by 6% to $8.7 million [4] - clonoSEQ test volume grew by 36% to 23,117 tests delivered compared to Q1 2024 [9] Financial Performance - Operating expenses for Q1 2025 were $82.0 million, down 9% from $90.6 million in Q1 2024 [5] - Net loss for Q1 2025 was $29.8 million, an improvement from a net loss of $47.5 million in the same period of 2024 [6] - Adjusted EBITDA for Q1 2025 was a loss of $12.7 million, compared to a loss of $28.2 million in Q1 2024 [6][27] Updated Financial Guidance - Full-year MRD revenue guidance was updated to $180 million to $190 million, implying annual growth of 24% to 31% [9] - Total company operating expenses are expected to be between $335 million and $345 million, down from the previous range of $340 million to $350 million [7] - Full-year cash burn is now projected to be between $50 million and $60 million, reduced from the earlier range of $60 million to $70 million [8]

Core Viewpoint - Dyadic International, Inc. is set to report its financial results for the first quarter of 2025 and will host a corporate update conference call on May 14, 2025 [1] Company Overview - Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for human and animal vaccines, therapeutics, and non-pharmaceutical applications such as food and industrial uses [4][6] - The company utilizes microbial gene expression and protein production platforms based on the fungus Thermothelomyces heterothallica, with its lead platform being the C1-cell protein production platform [5] Upcoming Conference Call - The conference call is scheduled for May 14, 2025, at 5:00 p.m. Eastern Time, with dial-in numbers provided for both toll-free and international participants [2] - A webcast link will be available for the live event, and an archive will be accessible within 24 hours [2] Contact Information - For inquiries, the Chief Financial Officer, Ping W. Rawson, can be contacted via phone or email [8]

Intellia Therapeutics, Inc. (NTLA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, NTLA broke out above the 50-day moving average, suggesting a short-term bullish trend.One of the three major moving averages, the 50-day simple moving average is commonly used by traders and analysts to determine support or resistance levels for different types of securities. However, the 50-day is considered to be more important since it's the first m ...